临床前203/212Pb-DOTA预靶向放射免疫治疗在人结直肠癌异种移植裸鼠中的研究
该临床前研究以抗GPA33双特异性抗体联合TCMC-Proteus放射配体构建DOTA预靶向放射免疫治疗(DOTA-PRIT),用203Pb进行生物分布与SPECT/CT成像并外推212Pb剂量学,在SW1222人结直肠癌异种移植裸鼠中确立双周期212Pb-DOTA-PRIT方案,显示疗效并实现部分组织学治愈,同时观察到骨髓正常与轻中度肾小管间质病变而肾功能总体保留。
要点
- GPA33预靶向[203Pb]Pb-TCMC-Pr在注射后24小时的肿瘤摄取为8.04 ± 2.94 %IA/g。
- 212Pb对肿瘤、血液和肾脏的剂量分别为12,723、313和1,075 mGy/MBq,对应治疗指数分别为40.6和11.8。
- 双周期方案(938 kBq + 938 kBq,间隔48小时,总计1.88 MBq)延长生存,研究终点137天时5只中3只组织学治愈。
核心结论
- 在临床前人结直肠癌模型中建立了安全且具治愈性的GPA33靶向212Pb-DOTA-PRIT治疗。
- 研究提示203/212Pb-DOTA-PRIT在结直肠癌管理中的潜力,并为其模块化应用于其他兼容DOTA-PRIT的靶抗原提供路线图。
研究设计与样本
- 研究为临床前裸鼠人结直肠癌(GPA33表达SW1222)异种移植模型研究。
- 合成TCMC-Proteus放射配体前体,制备[212Pb]Pb-TCMC-Pr并验证体外稳定性与双特异性抗体识别。
- 使用203Pb类似物进行系列生物分布与SPECT/CT成像,并外推212Pb剂量学。
- 建立抗GPA33 212Pb-DOTA-PRIT并开展治疗研究。
主要发现
- TCMC-Pr成功标记203Pb/212Pb,血清中稳定,并证实双特异性抗体特异性结合。
- GPA33预靶向[203Pb]Pb-TCMC-Pr注射后24小时血液、SW1222肿瘤和肾脏摄取分别为0.27 ± 0.14 %IA/g、8.04 ± 2.94 %IA/g和0.88 ± 0.14 %IA/g。
- 212Pb对肿瘤、血液和肾脏剂量分别为12,723 mGy/MBq、313 mGy/MBq(治疗指数40.6)和1,075 mGy/MBq(治疗指数11.8)。
- 双周期治疗方案(938 kBq + 938 kBq,间隔48小时,总计1.88 MBq)延长生存,研究终点137天时5只中3只组织学治愈。
- 该治疗组小鼠骨髓正常,肾小管间质病变轻中度,肾功能总体保留。
关键数值与推荐
- GPA33预靶向[203Pb]Pb-TCMC-Pr注射后24小时肿瘤摄取8.04 ± 2.94 %IA/g。
- 212Pb对肿瘤、血液、肾脏剂量分别为12,723、313、1,075 mGy/MBq,血液和肾脏治疗指数分别为40.6和11.8。
- 双周期方案为938 kBq + 938 kBq间隔48小时,总计1.88 MBq。
临床怎么用
- 临床前结果支持203/212Pb-DOTA-PRIT作为结直肠癌靶向α治疗的可模块化平台进一步转化研究。
- 双周期给药方案与剂量学数据可为后续临床剂量探索和安全性监测提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 203Pb (half-life [t1/2], 51.9 h) and 212Pb (t1/2 = 10.6 h) theranostic pair shows great potential for radiopharmaceutical therapy. We have developed a highly versatile pretargeted radioimmunotherapy (PRIT) platform that utilizes antitumor antigen/anti-DOTA bispecific antibodies (BsAbs) in combination with rapidly clearing, low-molecular-weight DOTA-radiohaptens (DOTA-PRIT). In this study, we tested the hypothesis that high-therapeutic index (TI) targeting of 212Pb (an in vivo generator of α-emitting progeny, specifically 212Bi (t1/2 = 1.01 h) and 212Po (t1/2 = 0.3 µs), and its imaging surrogate, 203Pb (γ-emitter, 279 keV), would be feasible with anti-glycoprotein A33 (GPA33) DOTA-PRIT for treatment of human colorectal cancer (CRC). Methods: For efficient and stable chelation of lead and high-affinity recognition by BsAbs, we synthesized a TCMC-based radiohapten precursor named TCMC-Proteus (TCMC-Pr). We prepared [212Pb]Pb-TCMC-Pr and confirmed its stability in vitro and recognition by BsAbs. Using the 203Pb analog, we conducted serial biodistribution and SPECT/CT imaging studies with a 3-step GPA33 DOTA-PRIT approach and extrapolated dosimetry for 212Pb. We then established anti-GPA33 212Pb-DOTA-PRIT in mouse xenografts of human CRC (GPA33-expressing SW1222). Results: TCMC-Pr was successfully radiolabeled with 203Pb/212Pb and verified stable in serum, and specific BsAb binding was confirmed. For GPA33-pretargeted [203Pb]Pb-TCMC-Pr, the blood, SW1222 tumor, and kidney uptakes at 24 h after injection were 0.27 ± 0.14 %IA/g, 8.04 ± 2.94 %IA/g, and 0.88 ± 0.14 %IA/g, respectively. 212Pb doses to tumor, blood, and kidneys were 12,723 mGy/MBq, 313 mGy/MBq (TI, 40.6), and 1,075 mGy/MBq (TI, 11.8), respectively. During 212Pb-DOTA-PRIT therapy studies, we established efficacy and identified a double-cycle treatment regimen (938 kBq + 938 kBq separated by 48 h; total, 1.88 MBq) that led to prolonged survival including 3 of 5 histologic cures at the study endpoint of 137 d. Mice in this treatment group exhibited normal bone marrows and moderate tubulointerstitial lesions, with overall preserved renal function. Conclusion: We have developed a safe, curative GPA33-targeted 212Pb-DOTA-PRIT treatment in a preclinical model of human CRC. This research underscores the potential of 203/212Pb-DOTA-PRIT in managing CRC and provides a road map for its modular application to other human tumor target antigens compatible with DOTA-PRIT.
引用
- Vaughn BA, Veach DR, Vargas DB, et al. Preclinical 203/212Pb-DOTA-Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal Cancer Xenografts. J Nucl Med. 2026. PMID: 41679925. doi:10.2967/jnumed.125.270604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。